Ke Zhan
Chongqing Medical University
9 Papers
8 Citations
Ke Zhan is an academic researcher from Chongqing Medical University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Ke Zhan,Yang Bai,Shengtao Liao,Hongyu Chen,Lili Kuang,Qingqing Luo,Lin Lv,Liewang Qiu,Zhechuan Mei +8 more
TL;DR: In this paper, a seven-gene signature associated with HCC progression was identified using weighted gene co-expression network analysis and least absolute shrinkage and selection operator, and its prognostic prediction value was confirmed in The Cancer Genome Atlas-liver HCC and International Cancer Gome Consortium liver cancer-RIKEN, Japan cohorts.
Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression
Li Zhong,Jinqiu Zhao,Lu Huang,Yi Li,Xiaoxiao Pang,Ke Zhan,Shan Li,Q. Xue,Xiaoli Pan,Liang Deng +9 more
TL;DR: Wang et al. as mentioned in this paper found that runt-related transcription factor 2 (Runx2) is associated with the development of non-alcoholic fatty liver disease, while its specific role in HSC activation and hepatic fibrosis remains elusive.
14
Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway.
TL;DR: AQP3 is a potential therapeutic target for improving the sensitivity of hypoxic HCC cells to sorafenib and is positively correlated with hypoxia-inducible factor-1α (HIF-1 α) levels.
Correlation of endoplasmic reticulum stress patterns with the immune microenvironment in hepatocellular carcinoma: a prognostic signature analysis
Ke Zhan,Xin Yang,Yang Bai +2 more
TL;DR: The data suggest that this novel ERS-associated gene signature could contribute to personalized cancer management for HCC and targeting GP6 inhibition might be a potential method for HCC therapy.
2
Peroxisomal trans-2-enoyl-CoA inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.
TL;DR: In this article , the role and mechanism of peroxisomal trans-2-enoyl-CoA reductase (PECR) in the genesis and development of liver cancer was investigated.
1